Subpopulations (%)

Patients with RMS (unfavorable tumor localization)

Control group

Р

CD3+ HLADR+

40.1 ± 6.9 (n = 12)

12.5 ± 2.0 (n = 12)

0.001

CD8+ HLADR+

32.5 ± 7.1 (n = 8)

8.9 ± 1.4 (n = 11)

0.001

CD3+ CD4+

30.3 ± 3.1 (n = 11)

39.3 ± 2.8 (n = 14)

0.046

Leu8+ CD4+

16.2 ± 4.3 (n = 8)

33.5 ± 4.7 (n = 10)

0.017

γδTCR-Т cells

16.7 ± 2.1 (n = 8)

9.6 ± 1.5 (n = 10)

0.013